Elena Maria Calosci

Dr. Elena Maria Calosci


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FMFruzsina Mezei
Fruzsina Mezei
ETEmmanouil Tsiasiotis
Emmanouil Tsiasiotis
MBMichele Basile
Michele Basile
ISIlaria Sciomenta
Ilaria Sciomenta
ECElena Maria Calosci
Elena Maria Calosci
DSDario Sacchini
Dario Sacchini
Introduction: Market access, pricing, and reimbursement of digital health technologies (DHTs) in Europe are significantly challenged by regulatory fragmentation and various assessment methodologies. Understanding the challenges and priorities of technology developers is essential for developing effective and relevant policy responses. This study explores perceived barriers and developer-driven priorities to inform the development of a harmonized health technology assessment (HTA) framework under the EDiHTA project. Methods: A mixed-methods approach was adopted, including a scoping review to identify key challenges, a survey of 20 DHT developers, and interviews and focus groups with 29 industry representatives from startups to multinational companies across 10 European countries during 2024. Results: Key challenges included a lack of transparency in reimbursement processes, fragmented HTA requirements, and misalignment between traditional evidence models and the agile development of DHTs. Developers highlighted the need to integrate real-world evidence, consider usability and implementation factors, and provide structured, lifecycle-based guidance. Financial barriers and procedural burdens were particularly significant for small and medium-sized enterprises. Conclusions: These findings highlight the need for an HTA framework that reflects the iterative nature of digital development, integrates real-world evidence, and reduces uncertainty for developers. The EDiHTA project aims to respond to these challenges by building a harmonized and flexible approach that aligns with the goals of the European HTA Regulation.

10 August 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
EBEugenio Di Brino
Eugenio Di Brino
ECElena Maria Calosci
Elena Maria Calosci
MBMichele Basile
Michele Basile
FRFilippo Rumi
Filippo Rumi
DADebora Antonini
Debora Antonini
Extending Italy’s mammography screening programme to women aged 45–49 and 70–74 could markedly improve breast-cancer prevention, lowering mortality and optimizing healthcare resources. Using a decision-tree model based on national epidemiological data, we compared the current screening coverage scenario, characterized by a partial regional adoption, with a nationwide optimal coverage extension. Under the current screening coverage scenario, the screening programme covers 1,995,876 eligible women, with a per-patient cost of €9.52. The model estimates 55,663 annual incident cases across the total eligible women, with approximately 13,975 diagnosed at an early stage and 41,688 at an advanced stage. Average disease-management costs amount to €135.84 per patient, resulting in a total per-patient expenditure (screening plus management) of approximately €145.36. The optimal screening coverage scenario extends coverage to the full eligible population of 3,930,936 women, increasing the per-patient cost to €18.75. Extended screening shifts stage distribution toward earlier detection, with approximately 19,430 early-stage cases and 36,233 advanced-stage cases. Per-patient disease-management costs fall to €126.05, for a total per-patient expenditure of approximately €144.80. The near-perfect equivalence between the two scenarios confirms that the intervention is essentially resource-neutral: the additional screening expenditure is almost entirely offset by savings in disease-management costs driven by earlier diagnosis, while enabling the identification of approximately 5,454 additional early-stage cases. Overall, full national extension would require additional investment, almost entirely offsetting costs for the Italian National Health Service (NHS) while improving equity and long-term sustainability through wider access to early diagnosis. Strategies to increase adherence, reduce regional inequalities, and integrate innovative technologies remain crucial, and inclusion of the programme in the Essential Levels of Care (LEA) would guarantee long-term equity and sustainability beyond cost savings.